Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06653842 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
A Phase 2 study of Cutaneous Venous Malformations, sponsored by Palvella Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 10
- Study locations
NCT06653842 is a Phase 2 study of Cutaneous Venous Malformations that is actively recruiting participants, run by Palvella Therapeutics. The registered enrollment target is 15 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT06653842, a Phase 2 study of Cutaneous Venous Malformations, is actively recruiting participants, sponsored by Palvella Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 10
- Study locations
Study Summary
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Conditions Studied
Interventions
- DRUG QTORIN 3.9% rapamycin anhydrous gel
Study Locations (10)
California
- Children's Hospital of Orange County - Irvine
- Stanford University - Palo Alto
Minnesota
- Minnesota Clinical Study Center - New Brighton
- Mayo Clinic - Rochester
Colorado
- Colorado Children's Hospital - Aurora
Maryland
- Johns Hopkins - Baltimore
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah Health - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06653842
The ClinicalTrials.gov registry entry for NCT06653842 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palvella Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Venous Malformations appearing as the primary indexed condition, and to 1 intervention - of which QTORIN 3.9% rapamycin anhydrous gel is the first listed.
NCT06653842 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Minnesota, Colorado.
Frequently Asked Questions
What is clinical trial NCT06653842 about?
NCT06653842 is a clinical study titled "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations". A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
What is the current status of trial NCT06653842?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-12-20. Estimated completion is 2026-03.
What conditions does trial NCT06653842 study?
This clinical trial studies the following conditions: Cutaneous Venous Malformations.
What interventions are being tested in trial NCT06653842?
The interventions under investigation include: QTORIN 3.9% rapamycin anhydrous gel (DRUG).
Who is sponsoring clinical trial NCT06653842?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06653842 being conducted?
This trial has 10 study locations across California, Colorado, Maryland, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.